IBI-10090

The lead pipeline product using the Verisome® technology is IBI-10090 which is being developed as a biodegradable therapeutic for injection of dexamethasone into the anterior chamber to treat inflammation associated with cataract surgery.

IBI-10090 will be Icon’s first product developed using the Verisome® technology to reach the market.  IBI-10090 is a biodegradable product for injection of dexamethasone into the anterior chamber to treat inflammation associated with cataract surgery.

IBI-10090 is intended to be injected into the anterior chamber of the eye immediately after cataract surgery and safely deliver therapeutic levels of the active ingredient, dexamethasone.

A Phase 3 trial is currently enrolling patients. More information can be found on clinicaltrials.gov.

Categories

Disclaimer

My Canadian Pharmacy is an informative service. All the information should not be used in the purposes to establish a diagnosis and prescribe a treatment plan. Our company is a vendor, not a drug manufacturer. We cooperate with drug manufacturers who distribute their products to us. We have no relation with Icon Bioscience and Verisome. They move to another domain. We bear no responsibility for any damage brought to your health. All the questions related to the drug quality should be addressed to the drug manufacturer directly.